Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial-mediated mechanism

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1535-1545

  Gajate, Consuelo ^a   An, Feiyun ^a,b   Mollinedo, Faustino ^a  

^a CSIC   (Spain)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; COMPLEMENTARY DNA; CURCUMIN; CYTOCHROME C; DEHYDRODIDEMNIN B; FAS ANTIBODY; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; P38 KINASE; PHOSPHOTRANSFERASE; PHYTOHEMAGGLUTININ; PROTEIN BCL 2; PROTEIN BID; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLOOD; CANCER CELL CULTURE; CELL ACTIVATION; CELL STRAIN L 929; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIVER CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANTHRACENES; ANTIGENS, CD95; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLOTTING, WESTERN; CARRIER PROTEINS; CASPASE 3; CASPASES; CELL LINE, TUMOR; CELLS, CULTURED; CURCUMIN; CYTOCHROMES C; DEPSIPEPTIDES; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLOW CYTOMETRY; GLUTATHIONE TRANSFERASE; HEPATOCYTES; HL-60 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; JURKAT CELLS; LEUKEMIA; MAP KINASE KINASE 4; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES, CYCLIC; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037388458     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Depenbrock, H., Peter, R., Faircloth, G. T., Manzanares, I., Jimeno, J., and Hanauske, A. R. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br. J. Cancer, 78: 739-744, 1998.
2. Geldof, A. A., Mastbergen, S. C., Henrar, R. E., and Faircloth, G. T. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother. Pharmacol., 44: 312-318, 1999.
3. Erba, E., Bassano, L., Di Liberti, G., Muradore, I., Chiorino, G., Ubezio, P., Vignati, S., Codegoni, A., Desiderio, M. A., Faircloth, G., Jimeno, J., and D'Incalci, M. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br. J. Cancer, 86: 1510-1517, 2002.
4. Rinehart, K. L., Jr., Gloer, J. B., Hughes, R. G., Jr., Renis, H. E., McGovren, J. P., Swynenberg, E. B., Stringfellow, D. A., Kuentzel, S. L., and Li, L. H. Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate. Science (Wash. DC), 212: 933-935, 1981.
5. Shin, D. M., Holoye, P. Y., Murphy, W. K., Forman, A., Papasozomenos, S. C., Hong, W. K., and Raber, M. Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting. Cancer Chemother. Pharmacol., 29: 145-149, 1991.
6. Shin, D. M., Holoye, P. Y., Forman, A., Winn, R., Perez-Soler, R., Dakhil, S., Rosenthal, J., Raber, M. N., and Hong, W. K. Phase II clinical trial of didemnin B in previously treated small cell lung cancer. Investig. New Drugs, 12: 243-249, 1994.
7. Weiss, R. B., Peterson, B. L., Allen, S. L., Browning, S. M., Duggan, D. B., and Schiffer, C. A. A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study. Investig. New Drugs, 12: 41-43, 1994.
8. Williamson, S. K., Wolf, M. K., Eisenberger, M. A., O'Rourke, M., Brannon, W., and Crawford, E. D. Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study. Investig. New Drugs, 13: 167-170, 1995.
9. Vera, M. D., and Joullie, M. M. Natural products as probes of cell biology: 20 years of didemnin research. Med. Res. Rev., 22: 102-145, 2002.
10. Crampton, S. L., Adams, E. G., Kuentzel, S. L., Li, L. H., Badiner, G., and Bhuyan, B. K. Biochemical and cellular effects of didemnins A and B. Cancer Res., 44: 1796-1801, 1984.
11. Li, L. H., Timmins, L. G., Wallace, T. L., Krueger, W. C., Prairie, M. D., and Im, W. B. Mechanism of action of didemnin B, a depsipeptide from the sea. Cancer Lett., 23: 279-288, 1984.
12. Crews, C. M., Collins, J. L., Lane, W. S., Snapper, M. L., and Schreiber, S. L. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 α. J. Biol. Chem., 269: 15411-15414, 1994.
13. Crews, C. M., Lane, W. S., and Schreiber, S. L. Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proc. Natl. Acad. Sci. USA, 93: 4316-4319, 1996.
14. Meng, L., Sin, N., and Crews, C. M. The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase. Biochemistry, 37: 10488-10492, 1998.
15. Grubb, D. R., Wolvetang, E. J., and Lawen, A. Didemnin B induces cell death by apoptosis: the fastest induction of apoptosis ever described. Biochem. Biophys. Res. Commun., 215: 1130-1136, 1995.
16. Johnson, K. L., Grubb, D. R., and Lawen, A. Unspecific activation of caspases during the induction of apoptosis by didemnin B in human cell lines. J. Cell. Biochem., 72: 269-278, 1999.
17. Grubb, D. R., Ly, J. D., Vaillant, F., Johnson, K. L., and Lawen, A. Mitochondrial cytochrome c release is caspase-dependent and does not involve mitochondrial permeability transition in didemnin B-induced apoptosis. Oncogene, 20: 4085-4094, 2001.
18. Ratter, F., Germer, M., Fischbach, T., Schulze-Osthoff, K., Peter, M. E., Droge, W., Krammer, P. H., and Lehmann, V. S-adenosylhomocysteine as a physiological modulator of Apo-1-mediated apoptosis. Int. Immunol., 8: 1139-1147, 1996.
19. Mollinedo, F., Fernandez-Luna, J. L., Gajate, C., Martin-Martin, B., Benito, A., Martinez-Dalmau, R., and Modolell, M. Selective induction of apoptosis in cancer cells by the ether lipid ET- 18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res., 57: 1320-1328, 1997.
20. Gajate, C., Fonteriz, R. I., Cabaner, C., Alvarez-Noves, G., Alvarez-Rodriguez, Y., Modolell, M., and Mollinedo, F. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int. J. Cancer, 85: 674-682, 2000.
21. Gomez-Lechon, M. J., Lopez, P., Donato, T., Montoya, A., Larrauri, A., Gimenez, P., Trullenque, R., Fabra, R., and Castell, J. V. Culture of human hepatocytes from small surgical liver biopsies. Biochemical characterization and comparison with in vivo. In Vitro Cell Dev. Biol., 26: 67-74, 1990.
22. Bort, R., Ponsoda, X., Jover, R., Gomez-Lechon, M. J., and Castell, J. V. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J. Pharmacol. Exp. Ther., 288: 65-72, 1999.
23. Ponsoda, X., Bort, R., Jover, R., Gomez-Lechon, M. J., and Castell, J. V. Increased toxicity of cocaine on human hepatocytes induced by ethanol: role of GSH. Biochem. Pharmacol., 58: 1579-1585, 1999.
24. Donato, M. T., Castell, J. V., and Gomez-Lechon, M. J. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab. Dispos., 23: 553-558, 1995.
25. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res., 47: 943-946, 1987.
26. Mollinedo, F., Martinez-Dalmau, R., and Modolell, M. Early and selective induction of apoptosis in human leukemic cells by the alkyllysophospholipid ET-18-OCH3. Biochem. Biophys. Res. Commun., 192: 603-609, 1993.
27. Mollinedo, F., Santos-Beneit, A. M., and Gajate, C. The human leukemia cell line HL-60 as a cell culture model to study neutrophil functions and inflammatory responses. In: M. Clynes (ed.), Animal Cell Culture Techniques, pp. 264-297. Heidelberg, Germany: Springer-Verlag, 1998.
28. Gajate, C., Barasoain, I., Andreu, J. M., and Mollinedo, F. Induction of apoptosis in leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-(2′, 3′, 4′-trimethoxyphenyl)-2, 4, 6-cycloheptatrien-1-one: protection by Bcl-2 and Bcl-X(L) and cell cycle arrest. Cancer Res., 60: 2651-2659, 2000.
29. Gajate, C., Santos-Beneit, A. M., Macho, A., Lazaro, M., Hernandez-De Rojas, A., Modolell, M., Munoz, E., and Mollinedo, F. Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. Int. J. Cancer, 86: 208-218, 2000.
30. Hibi, M., Lin, A., Smeal, T., Minden, A., and Karin, M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev., 7: 2135-2148, 1993.
31. Pique, M., Barragan, M., Dalmau, M., Bellosillo, B., Pons, G., and Gil, J. Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett., 480: 193-196, 2000.
32. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
33. Chen, Y. R., Wang, X., Templeton, D., Davis, R. J., and Tan, T. H. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and γ radiation. Duration of JNK activation may determine cell death and proliferation. J. Biol. Chem., 271: 31929-31936, 1996.
34. Gajate, C., Santos-Beneit, A., Modolell, M., and Mollinedo, F. Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-0-octadecyl-2-O- methyl-rac-glycero-3-phosphocholine. Mol. Pharmacol., 53: 602-612, 1998.
35. Chen, Y. R., and Tan, T. H. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene, 17: 173-178, 1998.
36. Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S., Manning, A. M., and Anderson, D. W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA, 98: 13681-13686, 2001.
37. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA, 92: 7686-7689, 1995.
38. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, R. L., Scherle, P. A., and Trzaskos, J. M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem., 273: 18623-18632, 1998.
39. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., and Lee, J. C. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett., 364: 229-233, 1995.
40. Kummer, J. L., Rao, P. K., and Heidenreich, K. A. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J. Biol. Chem., 272: 20490-20494, 1997.
41. Nicholson, D. W., and Thornberry, N. A. Caspases: killer proteases. Trends Biochem. Sci., 22: 299-306, 1997.
42. Janicke, R. U., Sprengart, M. L., Wati, M. R., and Porter, A. G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem., 273: 9357-9360, 1998.
43. Green, D., and Kroemer, G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol., 8: 267-271, 1998.
44. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94: 481-490, 1998.
45. Li, H., Zhu, H., Xu, C. J., and Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94: 491-501, 1998.
46. Perez-Sala, D., Collado-Escobar, D., and Mollinedo, F. Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease. J. Biol. Chem., 270: 6235-6242, 1995.
47. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature (Lond.), 364: 806-809, 1993.
48. Gajate, C., and Mollinedo, F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3) (Edelfosine), a proapoptotic agent in tumor cells. Curr. Drug Metab., 3: 491-525, 2002.
49. Cabaner, C., Gajate, C., Macho, A., Munoz, E., Modolell, M., and Mollinedo, F. Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system. Br. J. Pharmacol., 127: 813-825, 1999.
50. Gomez, S. G., Faircloth, G., Lopez-Lazaro, L., Jimeno, J., Bueren, J. A., and Albella, B. In vitro hematotoxicity of Aplidine on human bone marrow and cord blood progenitor cells. Toxicol. In Vitro, 15: 347-350, 2001.
51. Iijima, N., Miyamura, K., Itou, T., Tanimoto, M., Sobue, R., and Saito, H. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy. Blood, 90: 4901-4909, 1997.
52. Lewis, N. R., Pallis, M., and Russell, N. H. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia. Exp. Hematol., 28: 535-542, 2000.
53. Gajate, C., An, F., and Mollinedo, F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J. Biol. Chem., 277: 41580-41589, 2002.